Table 2.
Demographic features and the range of variables including clinical predictors measured in the subjects of the study cohort.
| Variable | BAT26 (N = 59) | D6S2881 (N = 81) | D6S2746 (N = 107) | D6S266 (N = 37) | D6S2666 (N = 97) | D6S2447 (N = 109) |
|---|---|---|---|---|---|---|
| Median age, y (Range) | 40 (26–77) | 40 (26–77) | 42 (28–77) | 37 (24–61) | 39 (24–66) | 39 (24–91) |
| Standard deviation | 9.7 | 9.7 | 9.6 | 8.4 | 8.7 | 10.6 |
| Age group (years) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| <30 | 1 (1.7) | 4 (4.9) | 5 (4.7) | 2 (5.4) | 6 (6.2) | 7 (6.4) |
| 30–40 | 30 (50.8) | 39 (48.1) | 46 (43) | 21 (56.8) | 54 (55.7) | 60 (54.5) |
| > 40 | 28 (47.5) | 38 (46.9) | 56 (52.3) | 14 (37.8) | 37 (38.1) | 42 (38.2) |
| HIV−1 status | ||||||
| HIV−1–positive | 36 (61) | 46 (56.8) | 56 (52.3) | 19 (51.4) | 62 (63.9) | 62 (56.9) |
| HIV−1–seronegative | 23 (39) | 35 (43.2) | 51 (47.7) | 18 (48.6) | 35 (36.1) | 47 (43.1) |
| *HPV infection | ||||||
| Single HPV infection | 19 (32.2) | 24 (29.6) | 36 (33.6) | 13 (35.1) | 33 (34) | 36 (33) |
| Multiple HPV infections | 33 (55.9) | 39 (48.1) | 50 (46.7) | 18 (48.6) | 48 (49.5) | 54 (49.5) |
| High risk HPV | 46 (78) | 59 (72.8) | 81 (75.7) | 27 (73) | 77 (79.4) | 86 (78.9) |
| Low risk HPV | 6 (10.2) | 4 (4.9) | 5 (4.7) | 4 (10.8) | 4 (4.1) | 4 (3.7) |
| Tumor stage | ||||||
| CIN 1 & 2 | 20 (33.9) | 31 (38.3) | 38 (35.5) | 17 (45.9) | 44 (45.4) | 49 (45) |
| CIN 3 | 16 (27.1) | 17 (21) | 25 (23.4) | 9 (24.3) | 25 (25.8) | 29 (26.6) |
| Invasive | 23 (39) | 33 (40.7) | 44 (41.1) | 11 (29.7) | 28 (28.9) | 31 (28.4) |
| Histopathology | ||||||
| Mild dysplasia | 9 (15.3) | 16 (19.8) | 19 (17.8) | 2 (5.4) | 16 (16.5) | 18 (16.5) |
| Moderate dysplasia | 11(18.6) | 15 (18.5) | 19 (17.8) | 15 (40.5) | 28 (28.9) | 31 (28.4) |
| Carcinoma In situ | 16 (27.1) | 17 (21) | 25 (23.4) | 9 (24.3) | 26 (26.8) | 29 (26.6) |
| Squamous cell carcinoma | 20 (33.9) | 26 (32.1) | 35 (32.7) | 8 (21.6) | 23 (23.7) | 24 (22) |
| Adenocarcinoma | 3 (5.1) | 7 (8.6) | 9 (8.4) | 3 (8.1) | 4 (4.1) | 7 (6.4) |
*
14 Invalid HPV results were omitted in the analyses. CIN 1, cervical intraepithelial neoplasia 1(Mild); CIN 2, cervical intraepithelial neoplasia 2 (Moderate); CIN 3, cervical intraepithelial neoplasia 3 (Severe or carcinoma in situ).